TriaCyte | cell therapy for solid tumors

Revolutionizing Cellular Therapy for Solid Tumors

Harnessing genetic engineering and AI, TriaCyte helps bring your cell therapies to solid tumors, boosting efficacy while reducing development time and cost

Abstract digital illustration of advanced cellular therapy targeting a solid tumor_ glowin

At the frontier of science and technology, we empower cell therapies to tackle hard-to-treat solid tumors.

Homing

Engineered immune cells guided with precision to locate and reach solid tumors

Infiltration

3D render of genetically engineered immune cells attacking a solid tumor in human tissue,

Specialized designs that enable immune cells to penetrate dense tumor environments

AI‑Driven Design

An abstract digital illustration showing artificial intelligence accelerating cellular the

Apply artificial intelligence for smarter CAR and immune cells selection

Our Team

Dr. Akram Obiedat

Co-founder and CEO

Dr. Obiedat has a PhD in pharmacology and immunology with over six years of experience in developing immunotherapies. As CEO of Triacyte, he leads the company’s vision to advance next‑generation treatments for solid tumors

Prof. Cyrille Cohen

Co-founder and Scientific Advisor

Prof. Cohen is Dean of the Faculty of Life Sciences at Bar‑Ilan University, leads the Tumor Immunology & Immunotherapy Lab, and is a member of Israel’s committees for the approval of gene and cell therapy clinical trials

Scientific Advisory Board

Marcela Maus, MD, PhD

Marcela Maus Innovator in Healthcare.JPG

Professor of Medicine

Director, Cancer Institute Program in Cellular Immunotherapy

Harvard Medical School

Mass General Brigham Cancer Institute

Saar Gill, MD, PhD

Professor of Medicine

Scientific Co-Director, Cell Therapy and Transplant Program

Hospital of the University of Pennsylvania